Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Assets (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Assets for 9 consecutive years, with $173.8 million as the latest value for Q4 2025.

  • Quarterly Assets fell 55.11% to $173.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $173.8 million through Dec 2025, down 55.11% year-over-year, with the annual reading at $173.8 million for FY2025, 55.11% down from the prior year.
  • Assets hit $173.8 million in Q4 2025 for Sutro Biopharma, down from $209.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $489.0 million in Q2 2024 to a low of $173.8 million in Q4 2025.
  • Historically, Assets has averaged $367.6 million across 5 years, with a median of $378.5 million in 2021.
  • Biggest five-year swings in Assets: surged 133.0% in 2021 and later crashed 55.11% in 2025.
  • Year by year, Assets stood at $341.4 million in 2021, then rose by 19.2% to $406.9 million in 2022, then rose by 15.68% to $470.7 million in 2023, then dropped by 17.74% to $387.2 million in 2024, then plummeted by 55.11% to $173.8 million in 2025.
  • Business Quant data shows Assets for STRO at $173.8 million in Q4 2025, $209.7 million in Q3 2025, and $262.4 million in Q2 2025.